| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(98)06020-6 |
| P698 | PubMed publication ID | 10023916 |
| P2093 | author name string | A K Burroughs | |
| D Patch | |||
| J Goulis | |||
| P2860 | cites work | The L-arginine-nitric oxide pathway | Q24304874 |
| Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway. Implications for vascular disease | Q24312335 | ||
| The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide | Q34063927 | ||
| Molecular characterization of endothelin receptors | Q35227688 | ||
| Endothelin receptors in rat liver: lipocytes as a contractile target for endothelin 1. | Q36583579 | ||
| Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells | Q39418552 | ||
| Hemodynamic factors involved in the development and rupture of esophageal varices: a pathophysiologic approach to treatment | Q39756178 | ||
| Pharmacodynamic profile of prostacyclin | Q40581672 | ||
| Why portal hypertensive varices bleed and bleed: a hypothesis | Q40612781 | ||
| Hepatic venous pressure measurement: an old test as a new prognostic marker in cirrhosis? | Q41293922 | ||
| Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells | Q42450671 | ||
| Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli | Q44505327 | ||
| Endotoxin alters arachidonate metabolism in pulmonary endothelial cells | Q45159821 | ||
| Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance | Q46185466 | ||
| Antibiotic prophylaxis for spontaneous bacterial peritonitis: how and whom? | Q54122329 | ||
| Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats. | Q54125651 | ||
| Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage | Q57181564 | ||
| Prognostic significance of bacterial infection in bleeding cirrhotic patients: A prospective study | Q58034650 | ||
| Hyperdynamic circulation in cirrhosis: a role for nitric oxide? | Q67684851 | ||
| Frequency of infections in cirrhotic patients presenting with acute gastrointestinal haemorrhage | Q68805077 | ||
| Inhibition of platelet aggregation by abnormal high density lipoprotein particles in plasma from patients with hepatic cirrhosis | Q69368276 | ||
| Cirrhotics with variceal hemorrhage: the importance of the time interval between admission and the start of analysis for survival and rebleeding rates | Q69738164 | ||
| Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium | Q69908131 | ||
| Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics | Q71586762 | ||
| Endothelin-1 induction of cyclooxygenase-2 expression in rat mesangial cells | Q72193010 | ||
| The endothelin system. A new target for therapeutic intervention | Q72285025 | ||
| Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia | Q72567619 | ||
| An endothelin receptor antagonist TAK-044 ameliorates carbon tetrachloride-induced acute liver injury and portal hypertension in rats | Q74456169 | ||
| Portal hypertension and variceal bleeding: an AASLD single topic symposium | Q77220747 | ||
| P433 | issue | 9147 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 139-142 | |
| P577 | publication date | 1999-01-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Bacterial infection in the pathogenesis of variceal bleeding. | |
| P478 | volume | 353 |
| Q35048025 | A case of bacteremia by Neisseria gonorrhoeae coincident with massive hemorrhage of esophageal varices |
| Q35765895 | A retrospective study of bacterial infections in cirrhosis. |
| Q34512090 | Acute variceal bleeding: general management. |
| Q50956831 | Acute-on-chronic liver failure. |
| Q45104707 | All beta-blockers are created equal, but some beta-blockers are more equal than others. |
| Q34546095 | Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial |
| Q41467673 | Antibiotic prophylaxis in the prevention of rebleeding in acute variceal hemorrhage: A randomized trial |
| Q37292296 | Antibiotic prophylaxis using third generation cephalosporins can reduce the risk of early rebleeding in the first acute gastroesophageal variceal hemorrhage: a prospective randomized study |
| Q53311100 | Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study. |
| Q44105999 | Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. |
| Q73755641 | Bacterial infections in patients with cirrhosis: reasons, comments and suggestions |
| Q41945346 | Circadian pattern of acute variceal bleeding among cirrhotic Egyptian patients |
| Q40422427 | Clinical implications of Paracoccus yeeii bacteremia in a patient with decompensated cirrhosis |
| Q98226101 | Coagulopathy and Hospital Outcomes in Patients With Spontaneous Bacterial Peritonitis: A Call for Action to Improve Care of Inpatients |
| Q35124682 | Current pharmacotherapy in the management of cirrhosis: focus on the hyperdynamic circulation |
| Q36012546 | Current research of hepatic cirrhosis in China |
| Q34959669 | Diagnosis and management of acute variceal bleeding: Asian Pacific Association for Study of the Liver recommendations |
| Q36582826 | Diagnosis and management of bacterial infections in decompensated cirrhosis |
| Q57010972 | Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices |
| Q36654490 | Effect of alternative antibiotics in treatment of cefotaxime resistant spontaneous bacterial peritonitis |
| Q36308577 | Effect of endotoxin on portal hemodynamic in rats |
| Q37257812 | Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice |
| Q43004018 | Endogenous heparinoids in acute variceal bleeding. |
| Q38256338 | Endoscopic treatment of esophageal varices in patients with liver cirrhosis |
| Q58421266 | Endotoxaemia, hyperfibrinolysis, and bleeding in cirrhosis |
| Q78402524 | Endotoxin and its binding proteins in chronic liver disease: the effect of transjugular intrahepatic portosystemic shunting |
| Q89017772 | Expression of α-Defensins, CD20+ B-lymphocytes, and Intraepithelial CD3+ T-lymphocytes in the Intestinal Mucosa of Patients with Liver Cirrhosis: Emerging Mediators of Intestinal Barrier Function |
| Q35588475 | F2-isoprostanes and the liver. |
| Q58034508 | Faut-il surveiller l’efficacité des traitements pharmacologiques et si oui, comment ? |
| Q34446521 | Future therapy of portal hypertension in liver cirrhosis - a guess |
| Q37613589 | Gluing gastric varices in 2012: lessons learnt over 25 years |
| Q42774107 | Gut flora and bacterial translocation in chronic liver disease |
| Q48734941 | Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure [Lancet 1956;2:1221-1225]. |
| Q43230885 | Heparin effect on thromboelastography after transjugular intrahepatic portosystemic shunt procedure |
| Q26864350 | Hepatosplanchnic circulation in cirrhosis and sepsis |
| Q64105998 | Immune Dysfunction and Albumin-Related Immunity in Liver Cirrhosis |
| Q43737734 | Increased formation of S-nitrothiols and nitrotyrosine in cirrhotic rats during endotoxemia |
| Q43261911 | Increased plasma malondialdehyde in patients with viral cirrhosis and its relationships to plasma nitric oxide, endotoxin, and portal pressure |
| Q41811300 | Increased serum activity of matrix metalloproteinase-9 in patients with acute variceal bleeding |
| Q74645226 | Infection and hemostasis in decompensated cirrhosis: a prospective study using thrombelastography |
| Q34400962 | Infection, coagulation, and variceal bleeding in cirrhosis |
| Q35768917 | Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats |
| Q41036794 | Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications |
| Q42468400 | Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis. |
| Q36153972 | Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis? |
| Q87200165 | Liver cirrhosis |
| Q42839470 | Liver: Can pentoxifylline secure its place in liver therapeutics? |
| Q34036903 | Management of acute variceal bleeding |
| Q37980891 | Management of bacterial infections in cirrhosis. |
| Q39367875 | Management of hypersplenism in non-cirrhotic portal hypertension: a surgical series |
| Q80988416 | Management of portal hypertension |
| Q37832507 | Management of varices in cirrhosis |
| Q38094881 | Management of varices in patients with cirrhosis |
| Q21284997 | Microbial translocation in chronic liver diseases |
| Q33866656 | New insights into the coagulopathy of liver disease and liver transplantation |
| Q38314866 | No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion |
| Q37278085 | Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment |
| Q34269668 | Portal hypertension |
| Q43320795 | Potential Precipitating Factors of Esophageal Variceal Bleeding: A Case–Control Study |
| Q35744431 | Predicting risk factors for rebleeding, infections, mortality following peptic ulcer bleeding in patients with cirrhosis and the impact of antibiotics prophylaxis at different clinical stages of the disease. |
| Q74034534 | Predictive factors for failure to control bleeding in cirrhotic patients |
| Q44591186 | Predictors and Implications of Severe Hypersplenism in Patients with Cirrhosis |
| Q77424954 | Presence of bacterial infection in bleeding cirrhotic patients is independently associated with early mortality and failure to control bleeding |
| Q38229031 | Primary prevention of bleeding from esophageal varices in patients with liver cirrhosis |
| Q26852622 | Primary prevention of variceal bleeding: pharmacological therapy versus endoscopic banding |
| Q54706189 | Pro: Cirrhotic patients with small esophageal varices should undergo primary prophylaxis. |
| Q73363189 | Probiotics for the hemodynamic alterations of patients with liver cirrhosis |
| Q37898517 | Probiotics in hepatology. |
| Q40328812 | Prognostic factors associated with mortality in patients with gastric fundal variceal bleeding |
| Q37590104 | Recurrent bacteremia, a complication of cyanoacrylate injection for variceal bleeding: report of two cases and review of the literature. |
| Q33904314 | Review article: pharmacological treatment of the hepatorenal syndrome in cirrhotic patients |
| Q33961964 | Review article: primary prophylaxis for portal hypertensive bleeding in cirrhosis |
| Q39365144 | Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis. |
| Q36653858 | Role of Kupffer cells in host defense and liver disease |
| Q42321783 | Selective Intestinal Decontamination in Portal Hypertension |
| Q35597315 | Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. |
| Q33787621 | Serum levels of soluble Fas, nitric oxide and cytokines in acute decompensated cirrhotic patients |
| Q24649027 | Spontaneous bacterial peritonitis: a severe complication of liver cirrhosis |
| Q37791935 | Spontaneous bacterial peritonitis: from pathophysiology to prevention |
| Q33424708 | Spontaneous bleeding or thrombosis in cirrhosis: What should be feared the most? |
| Q37855600 | The effects of cefazolin on cirrhotic patients with acute variceal hemorrhage after endoscopic interventions |
| Q43868202 | The low incidence of bacterial infections could be a protective factor against variceal bleeding per se in hemodynamic responders to propranolol. |
| Q42785969 | Thrombocytopenia associated with chronic liver disease: effects of rifaximin on platelet count |
| Q35852609 | Towards noninvasive detection of oesophageal varices |
| Q90911148 | Treatment outcomes in patients with pyogenic vertebral osteomyelitis who have cirrhosis |
| Q42472251 | Treatment with the leukotriene inhibitor montelukast for 10 days attenuates portal hypertension in rat liver cirrhosis. |
| Q41843561 | Upper gastrointestinal haemorrhage: an update |
| Q73542378 | [Consensus on spontaneous bacterial peritonitis in liver cirrhosis: diagnosis, treatment, and prophylaxis] |
| Q80221005 | [Functional component of portal hypertension] |
| Q80103186 | [Gastrointestinal hemorrhage. Failure of pharmacological and endoscopic treatments: what is to be done?] |
| Q79711880 | [Infection and variceal bleeding in cirrhosis] |
Search more.